Eli Lilly to plead guilty to false advertising of Evista

December 22, 2005 at 10:38 pm Leave a comment

Eli Lilly and Co. accepted a $36 million fine and will plead guilty to a federal misdemeanor charge due to false advertising for its Evista osteoporosis medication for breast cancer and cardiovascular risk reduction. The company’s Evista advertising will also be subject to strict guidelines and federal oversight for five years. The Food and Drug Administration has not approved Evista for breast cancer treatment or cardiovasvular risk reduction, but the drug has been approved for preventing and treating osteoporosis in post-menopausal women.

See Eli Lilly Pleads Guilty in Marketing Promotion, Brandweek (Dec. 22, 2005).

Advertisements

Entry filed under: All Posts, DTC, False Advertising.

Jones Day gains injunction against “parody” site. Cal. Supremes extinguish tobacco co.’s fed. defense

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

Trackback this post  |  Subscribe to the comments via RSS Feed


Calendar

December 2005
M T W T F S S
« Nov   Jan »
 1234
567891011
12131415161718
19202122232425
262728293031  

Most Recent Posts


%d bloggers like this: